Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab

Abstract Background Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive tumor with a poor prognosis and standard therapy has not yet been established. Case A 65‐year‐old male with a cough for 2 months presented to our hospital. He was clinically diagnosed with non small ce...

Full description

Bibliographic Details
Main Authors: Naoki Kadota, Nobuo Hatakeyama, Hiroyuki Hino, Michihiro Kunishige, Yoshihiro Kondo, Yoshio Okano, Hisanori Machida, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Fumitaka Ogushi, Eiji Takeuchi
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Cancer Reports
Subjects:
complete response
immune checkpoint inhibitor
pembrolizumab
plasma cell
pulmonary large cell neuroendocrine carcinoma
Online Access:https://doi.org/10.1002/cnr2.1589

Internet

https://doi.org/10.1002/cnr2.1589

Similar Items